LGL Group (NYSEAMERICAN:LGL) Stock Price Passes Above 200-Day Moving Average – Here’s Why

LGL Group, Inc. (The) (NYSEAMERICAN:LGL) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $6.48 and traded as high as $7.38. LGL Group shares last traded at $7.26, with a volume of 2,083 shares trading hands.

LGL Group Stock Performance

The stock has a market cap of $47.41 million, a price-to-earnings ratio of 42.71 and a beta of 0.31. The business’s fifty day simple moving average is $7.11 and its 200 day simple moving average is $6.48.

Insider Activity at LGL Group

In other LGL Group news, major shareholder Mario J. Gabelli purchased 95,387 shares of LGL Group stock in a transaction that occurred on Tuesday, December 30th. The stock was purchased at an average price of $4.75 per share, with a total value of $453,088.25. Following the completion of the acquisition, the insider owned 572,324 shares of the company’s stock, valued at approximately $2,718,539. This trade represents a 20.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 18.90% of the company’s stock.

Institutional Investors Weigh In On LGL Group

A hedge fund recently bought a new stake in LGL Group stock. Citadel Advisors LLC bought a new stake in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned approximately 0.25% of LGL Group as of its most recent SEC filing. Institutional investors and hedge funds own 30.28% of the company’s stock.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.